Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4198)	5/4/1998 3:33:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Isaac, thanks for providing the info...now who would jump all over you...just give me their address.<g> I thought I heard CNBC state the ENMD product is about a year away from human testing. I also thought I heard the effective rate was near 100%...someone please correct me if I'm wrong. Am I to understand the AGPH product is based on the same technology as ENMD's? Did AGPH tell you when they might release further information? If I were to guess, it's not the lack of bragging that's holding the stock back, it's the lack of news of any kind. What would be considered a normal time lapse between the suggestion of a drug entering a new phase of trials and the release information regarding the previous phase? I have no idea. I find the silence disturbing, but as I've stated before, am not familiar with standard practice in these situations. sf

To: Izzy who wrote (4198)	5/4/1998 3:33:00 PM
From: per strandberg	Respond to of 6136

Isaac, I find this site very useful for info about cancer drugs. slip.net Regards ps

To: Izzy who wrote (4198)	5/4/1998 3:48:00 PM
From: margie	Read Replies (2) \| Respond to of 6136

Agouron's Matrix Mettalloprotease (MMP)- AG3340 is directly anti-angiogenic. Phase III clinical trials were started at the end of the last quarter (March, 98). AG3340 will be an oral pill, as opposed to Entremeds which needs to be injected. AG3340 is a small synthetic molecule. Agouron probably has the largest number of anti-angiogenic programs and is probably one of the furthest along in clinical trials (in humans, as opposed to mice) for small molecule synthetic products. AG3340 is in Phase III for non-small cell lung cancer, in combination with two anticancer drugs. It is also in Phase III for hormone-refractory prostate cancer in combination with mitoxantrone/prednisone. Agouron hopes to have an application for AG3340 by the end of 2000, maybe a little before. As we have heard all day on CNBC, Entremed's Phase I clinical trials (in humans) are estimated to begin in one year. "MMPs have been associated with tumor growth, the spread of tumor cells to secondary sites within the body (metastasis), and the growth of new blood vessels (angiogenesis), through which tumor cells obtain nutrients and growth factors." Agouron believes that their MMP inhibitors, both first generation and second generation, are more specific than ones like Marimastat from British Biotech, as they are more selective and do not inhibit all MMPs as some MMP's are necessary for normal cell funtion and growth. Agouron is also examining the use of AG3340 in the field of opthalmology, against macular degeneration and will be presenting pre-clinical (animal) results at a Vision and Opthamology conference in Florida scheduled immediately before ASCO, in May, I think. Not sure of the date. Also, some Phase I dosing data on AG2034 will be released at this meeting. From the web site: Agouron has recently initiated a drug discovery program whose objective is the design of drugs that block the kdr receptor for VEGF and therefore compromise the ability of tumors to carry out a key process in angiogenesis. This is still in the research stage.

To: Izzy who wrote (4198)	5/4/1998 4:47:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 6136

It is nice that the most advanced Agouron cancer drug is an anti angiogenesis drug and I am beginning to get cautious about cancer biotechs that don't have an anti angiogenesis drug in their pipeline. But there is a big difference between the average anti angiogenesis drug which is more or less effective against cancer and endostatin in mice which shrinks tumors to insignificance and seems to keeps all of the treated mice alive indefinitely. (T. Boehm et. al. - Nature, vol 390, 27. november 1997, pages 404-407) Andreas